Prothena Expects $72 Million Net Cash Use in 2026
The Company expects its full year net cash used in operating and investing activities to be $50 to $55 million and to end the year with approximately $255 million (midpoint) in cash, cash equivalents, and restricted cash. The estimated full year 2026 net cash used from operating and investing activities is primarily driven by an estimated net loss of $67 to $72 million, which includes an estimated $24 million of non-cash share-based compensation expense. This financial guidance does not include the potential to earn up to $105 million of aggregate clinical milestone payments from strategic partners in 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb. "In 2025, our partner Roche initiated the Phase 3 PARAISO clinical trial evaluating prasinezumab in early Parkinson's disease and Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy, both with primary completions expected in 2029. In addition, we expect our partner Bristol Myers Squibb to decide on the potential advancement of PRX019 in 2026 and to complete the ongoing Phase 2 TargetTau-1 clinical trial evaluating BMS-986446 in early Alzheimer's in 1H 2027. These partnered programs have the potential to earn up to approximately $3 billion in future aggregate milestones in addition to potential future royalties," said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. "We also unveiled our proprietary CYTOPE(R) technology with presentations at scientific congresses highlighting preclinical data from our TDP-43 CYTOPE(R) program. In addition, we are evaluating PRX012-TfR, our once-monthly, subcutaneous anti-Abeta antibody combined with transferrin receptor technology for the treatment of Alzheimer's in preclinical studies. We expect to share more data from our preclinical programs later this year."
Trade with 70% Backtested Accuracy
Analyst Views on PRTA
About PRTA
About the author
Prothena Authorizes $100 Million Share Buyback Plan
- Share Buyback Plan: Prothena's board has authorized a share repurchase plan allowing for the buyback of up to $100 million in outstanding shares, aimed at enhancing shareholder value and boosting market confidence, which is expected to positively impact the stock price.
- Strong Cash Position: As of December 31, 2025, Prothena reported $308.4 million in cash and cash equivalents with no debt, indicating robust financial health that supports the buyback initiative.
- Future Cash Expectations: Excluding the buyback plan, Prothena anticipates ending 2026 with approximately $255 million in cash and cash equivalents, ensuring operational flexibility for future investments and initiatives.
- Clinical Milestone Potential: The company expects to earn up to $105 million in clinical milestone payments in 2026, linked to strategic partnerships with Novo Nordisk and Bristol Myers Squibb, highlighting its potential in treating ATTR amyloidosis and neurodegenerative diseases.
Prothena Board Approves $100 Million Share Repurchase Plan
- Repurchase Plan Initiated: Prothena's board has authorized a share repurchase plan of up to $100 million, aimed at enhancing shareholder value and boosting market confidence, which is expected to have a positive impact on the stock price.
- Strong Financial Position: As of December 31, 2025, the company reported $308.4 million in cash and cash equivalents with no debt, indicating robust financial health that supports the repurchase plan.
- Future Cash Projections: Excluding any purchases under the plan, Prothena expects to end 2026 with approximately $255 million in cash, providing a stable financial foundation for future R&D and operations.
- Clinical Milestone Potential: The company anticipates earning up to $105 million in aggregate clinical milestone payments in 2026, which will further enhance its financial flexibility and support collaborative projects with Novo Nordisk and Bristol Myers Squibb.
Prothena Q4 Earnings Report Analysis
- Earnings Performance: Prothena reported a Q4 GAAP EPS of -$0.40, beating expectations by $0.16, indicating some improvement in cost management; however, the continued losses highlight ongoing financial pressures.
- Revenue Decline: The company generated only $0.02 million in revenue, a staggering 99.1% year-over-year decline, missing market expectations by $0.65 million, which signals severe challenges in product sales and market demand that could impact future liquidity.
- Investor Conference Participation: Prothena presented at the Evercore 8th Annual Healthcare Conference, and while the financial performance was disappointing, such events can enhance visibility among investors and potentially create future financing opportunities.
- Historical Financial Data: Historical earnings data for Prothena shows significant volatility in performance over recent quarters, with ongoing losses and declining revenues likely to affect its long-term strategy and market confidence.
Prothena Board Member Paula Cobb Resigns to Join Manifold Bio as COO
- Board Change: Prothena Corporation announces that Paula Cobb will step down from the board to become COO at Manifold Bio, having made significant contributions to the company's vision and strategy during her six-year tenure.
- Leadership Impact: Board Chair Daniel G. Welch expressed gratitude for Cobb's contributions, highlighting her extensive experience in global development, business strategy, and commercial expertise that provided valuable insights to the board and leadership.
- Current Board Status: With Cobb's departure, Prothena's board now consists of 8 directors, which may impact the company's future strategic decisions and governance structure.
- Company Vision: In her farewell, Cobb reaffirmed her confidence in Prothena's strategic vision, emphasizing the company's commitment to developing transformative medicines for severe diseases caused by protein dysregulation.
Amazon Set to Surge by 31%? Check Out 10 Leading Analyst Predictions for Monday
Analyst Upgrades and Downgrades: JP Morgan downgraded Argan Inc while raising its price target, Oppenheimer maintained an Outperform rating for Amazon with a price target increase, and RBC Capital downgraded PTC Therapeutics despite raising its price target.
Price Target Adjustments: Barclays lowered Crown Castle's price target and downgraded its rating, while Benchmark raised Light & Wonder's target and maintained a Buy rating.
Significant Increases: Mizuho raised Insmed's price target significantly and maintained an Outperform rating, while HSBC upgraded Thermo Fisher Scientific from Hold to Buy with a notable price target increase.
Mixed Ratings: Argus Research cut Target's price target but kept a Buy rating, and BMO Capital reduced Old Dominion's target while upgrading its rating to Outperform.
Novo Nordisk's Coramitug, a $100 Million Investment, Shows Potential in Lowering Heart Failure Biomarkers
Phase 2 Trial Results: Novo Nordisk's coramitug, an antibody for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), showed a significant reduction in NT-proBNP levels at a 60 mg/kg dose, indicating potential effectiveness, though it did not significantly impact the six-minute walk test.
Background on Coramitug: Originally developed by Prothena Corporation and acquired by Novo Nordisk in 2021, coramitug targets misfolded transthyretin to promote amyloid clearance and is currently being evaluated in a Phase 3 trial named CLEOPATTRA.
Participant Demographics: The trial involved 104 participants, with 90% on disease-modifying therapy, primarily using Pfizer's Vyndaqel/Vyndamax, and demonstrated that coramitug was well tolerated with improved echocardiographic parameters.
Market Impact: Following the trial results, Novo Nordisk's stock saw a slight increase of 0.87% in premarket trading, reflecting investor interest in the potential of coramitug in treating ATTR-CM.
Prothena Authorizes $100 Million Share Buyback Plan
- Share Buyback Plan: Prothena's board has authorized a share repurchase plan allowing for the buyback of up to $100 million in outstanding shares, aimed at enhancing shareholder value and boosting market confidence, which is expected to positively impact the stock price.
- Strong Cash Position: As of December 31, 2025, Prothena reported $308.4 million in cash and cash equivalents with no debt, indicating robust financial health that supports the buyback initiative.
- Future Cash Expectations: Excluding the buyback plan, Prothena anticipates ending 2026 with approximately $255 million in cash and cash equivalents, ensuring operational flexibility for future investments and initiatives.
- Clinical Milestone Potential: The company expects to earn up to $105 million in clinical milestone payments in 2026, linked to strategic partnerships with Novo Nordisk and Bristol Myers Squibb, highlighting its potential in treating ATTR amyloidosis and neurodegenerative diseases.
Prothena Board Approves $100 Million Share Repurchase Plan
- Repurchase Plan Initiated: Prothena's board has authorized a share repurchase plan of up to $100 million, aimed at enhancing shareholder value and boosting market confidence, which is expected to have a positive impact on the stock price.
- Strong Financial Position: As of December 31, 2025, the company reported $308.4 million in cash and cash equivalents with no debt, indicating robust financial health that supports the repurchase plan.
- Future Cash Projections: Excluding any purchases under the plan, Prothena expects to end 2026 with approximately $255 million in cash, providing a stable financial foundation for future R&D and operations.
- Clinical Milestone Potential: The company anticipates earning up to $105 million in aggregate clinical milestone payments in 2026, which will further enhance its financial flexibility and support collaborative projects with Novo Nordisk and Bristol Myers Squibb.
Prothena Q4 Earnings Report Analysis
- Earnings Performance: Prothena reported a Q4 GAAP EPS of -$0.40, beating expectations by $0.16, indicating some improvement in cost management; however, the continued losses highlight ongoing financial pressures.
- Revenue Decline: The company generated only $0.02 million in revenue, a staggering 99.1% year-over-year decline, missing market expectations by $0.65 million, which signals severe challenges in product sales and market demand that could impact future liquidity.
- Investor Conference Participation: Prothena presented at the Evercore 8th Annual Healthcare Conference, and while the financial performance was disappointing, such events can enhance visibility among investors and potentially create future financing opportunities.
- Historical Financial Data: Historical earnings data for Prothena shows significant volatility in performance over recent quarters, with ongoing losses and declining revenues likely to affect its long-term strategy and market confidence.
Prothena Board Member Paula Cobb Resigns to Join Manifold Bio as COO
- Board Change: Prothena Corporation announces that Paula Cobb will step down from the board to become COO at Manifold Bio, having made significant contributions to the company's vision and strategy during her six-year tenure.
- Leadership Impact: Board Chair Daniel G. Welch expressed gratitude for Cobb's contributions, highlighting her extensive experience in global development, business strategy, and commercial expertise that provided valuable insights to the board and leadership.
- Current Board Status: With Cobb's departure, Prothena's board now consists of 8 directors, which may impact the company's future strategic decisions and governance structure.
- Company Vision: In her farewell, Cobb reaffirmed her confidence in Prothena's strategic vision, emphasizing the company's commitment to developing transformative medicines for severe diseases caused by protein dysregulation.
Amazon Set to Surge by 31%? Check Out 10 Leading Analyst Predictions for Monday
Analyst Upgrades and Downgrades: JP Morgan downgraded Argan Inc while raising its price target, Oppenheimer maintained an Outperform rating for Amazon with a price target increase, and RBC Capital downgraded PTC Therapeutics despite raising its price target.
Price Target Adjustments: Barclays lowered Crown Castle's price target and downgraded its rating, while Benchmark raised Light & Wonder's target and maintained a Buy rating.
Significant Increases: Mizuho raised Insmed's price target significantly and maintained an Outperform rating, while HSBC upgraded Thermo Fisher Scientific from Hold to Buy with a notable price target increase.
Mixed Ratings: Argus Research cut Target's price target but kept a Buy rating, and BMO Capital reduced Old Dominion's target while upgrading its rating to Outperform.
Novo Nordisk's Coramitug, a $100 Million Investment, Shows Potential in Lowering Heart Failure Biomarkers
Phase 2 Trial Results: Novo Nordisk's coramitug, an antibody for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), showed a significant reduction in NT-proBNP levels at a 60 mg/kg dose, indicating potential effectiveness, though it did not significantly impact the six-minute walk test.
Background on Coramitug: Originally developed by Prothena Corporation and acquired by Novo Nordisk in 2021, coramitug targets misfolded transthyretin to promote amyloid clearance and is currently being evaluated in a Phase 3 trial named CLEOPATTRA.
Participant Demographics: The trial involved 104 participants, with 90% on disease-modifying therapy, primarily using Pfizer's Vyndaqel/Vyndamax, and demonstrated that coramitug was well tolerated with improved echocardiographic parameters.
Market Impact: Following the trial results, Novo Nordisk's stock saw a slight increase of 0.87% in premarket trading, reflecting investor interest in the potential of coramitug in treating ATTR-CM.
